Breaking bad family ties: Pan-ERBB blockers inhibit KRAS driven lung tumorigenesis

Oncogenic K-RAS mutations were believed to lock the molecular switch in the ON state, independent of upstream activation. However, we demonstrate in preclinical models that activity of mutated K-RAS depends on upstream signaling events involving EGF receptor family members. This finding reveals a po...

Descripción completa

Detalles Bibliográficos
Autores principales: Moll, Herwig P., Casanova, Emilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Author’s Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276852/
https://www.ncbi.nlm.nih.gov/pubmed/30525091
http://dx.doi.org/10.1080/23723556.2018.1513724
_version_ 1783378079901548544
author Moll, Herwig P.
Casanova, Emilio
author_facet Moll, Herwig P.
Casanova, Emilio
author_sort Moll, Herwig P.
collection PubMed
description Oncogenic K-RAS mutations were believed to lock the molecular switch in the ON state, independent of upstream activation. However, we demonstrate in preclinical models that activity of mutated K-RAS depends on upstream signaling events involving EGF receptor family members. This finding reveals a potential therapeutic vulnerability using pan-ERBB inhibitors to fight K-RAS mutated lung tumors.
format Online
Article
Text
id pubmed-6276852
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-62768522019-09-20 Breaking bad family ties: Pan-ERBB blockers inhibit KRAS driven lung tumorigenesis Moll, Herwig P. Casanova, Emilio Mol Cell Oncol Author’s Views Oncogenic K-RAS mutations were believed to lock the molecular switch in the ON state, independent of upstream activation. However, we demonstrate in preclinical models that activity of mutated K-RAS depends on upstream signaling events involving EGF receptor family members. This finding reveals a potential therapeutic vulnerability using pan-ERBB inhibitors to fight K-RAS mutated lung tumors. Taylor & Francis 2018-09-20 /pmc/articles/PMC6276852/ /pubmed/30525091 http://dx.doi.org/10.1080/23723556.2018.1513724 Text en © 2018 The Author(s). Published by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Author’s Views
Moll, Herwig P.
Casanova, Emilio
Breaking bad family ties: Pan-ERBB blockers inhibit KRAS driven lung tumorigenesis
title Breaking bad family ties: Pan-ERBB blockers inhibit KRAS driven lung tumorigenesis
title_full Breaking bad family ties: Pan-ERBB blockers inhibit KRAS driven lung tumorigenesis
title_fullStr Breaking bad family ties: Pan-ERBB blockers inhibit KRAS driven lung tumorigenesis
title_full_unstemmed Breaking bad family ties: Pan-ERBB blockers inhibit KRAS driven lung tumorigenesis
title_short Breaking bad family ties: Pan-ERBB blockers inhibit KRAS driven lung tumorigenesis
title_sort breaking bad family ties: pan-erbb blockers inhibit kras driven lung tumorigenesis
topic Author’s Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276852/
https://www.ncbi.nlm.nih.gov/pubmed/30525091
http://dx.doi.org/10.1080/23723556.2018.1513724
work_keys_str_mv AT mollherwigp breakingbadfamilytiespanerbbblockersinhibitkrasdrivenlungtumorigenesis
AT casanovaemilio breakingbadfamilytiespanerbbblockersinhibitkrasdrivenlungtumorigenesis

Ejemplares similares